Gangadhara Ganapati

USPTO Granted Patents = 10 (Patent Applications = 24)

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 1 (Patent Applications = 7)

Average Co-Inventor Count = 4.0

ph-index = 5

Forward Citations = 91(Granted Patents)

Company Filing History:

Adamas Pharmaceuticals, Inc.

patents

Years Active: 2014-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12178827 - Nicotinyl riboside compounds and their uses (2024-12-31),

2. 12168673 - Prodrugs derived from nicotinic acid and ribose (2024-12-17),

3. 11833167 - Nicotinyl riboside compounds and their uses (2023-12-05),

4. 11286274 - Nicotinamide riboside derivatives and their uses (2022-03-29),

5. 11197835 - Method of administering amantadine prior to a sleep period (2021-12-14),

6. 9877933 - Method of administering amantadine prior to a sleep period (2018-01-30),

7. 9867793 - Method of administering amantadine prior to a sleep period (2018-01-16),

8. 9867792 - Method of administering amantadine prior to a sleep period (2018-01-16),

9. 9867791 - Method of administering amantadine prior to a sleep period (2018-01-16),

10. 8741343 - Method of administering amantadine prior to a sleep period (2014-06-03),

Title: Gangadhara Ganapati: Innovator in Mitochondrial Health

Introduction

Gangadhara Ganapati is a prominent inventor based in Palo Alto, CA, known for his significant contributions to the field of mitochondrial health. With a total of 10 patents to his name, he has made remarkable advancements in the understanding and treatment of mitochondrial dysfunction.

Latest Patents

His latest patents include innovative compounds such as nicotinyl riboside and its derivatives. These compounds, including nicotinamide riboside (NR) and nicotinic acid riboside (NAR), have shown improved stability and bioavailability. They are designed to increase intracellular NAD+ levels, enhancing mitochondrial and cellular function. Furthermore, these compounds are useful in treating various mitochondrial diseases and related disorders. Another notable patent involves prodrugs derived from nicotinic acid and ribose, which can be utilized to treat a range of medical disorders characterized by mitochondrial dysfunction.

Career Highlights

Throughout his career, Ganapati has worked with notable companies such as Adamas Pharma and Mitopower. His work has focused on developing therapeutic agents that address critical health issues related to mitochondrial function.

Collaborations

He has collaborated with esteemed colleagues, including Gregory T Went and Gayatri Sathyan, contributing to the advancement of research in his field.

Conclusion

Gangadhara Ganapati's innovative work in mitochondrial health has the potential to transform treatment options for various disorders. His patents reflect a commitment to improving human health through scientific discovery.

This text is generated by artificial intelligence and may not be accurate.